6:11 PM
Sep 25, 2013
 |  BC Extra  |  Clinical News

Myriad Genetics reports data for lung cancer test

Myriad Genetics Inc. (NASDAQ:MYGN) reported data from a validation study analyzing tumor samples from 841 patients with early stage, resectable lung adenocarcinoma showing that its...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >